Nucleai

Nucleai’s technology leverages intelligence-grade geospatial AI methods to analyze and interpret complex cellular interactions in a patient’s biopsy, translating them into actionable insights that can accelerate the development of life-saving treatments and diagnostics. The company deploys an AI spatial tool for patient selection in a clinical trial, in partnership with a top 10 biopharma company. The platform pioneers AI-driven spatial biomarker analysis, offering a first-of-its-kind multimodal solution. It ingests images from various modalities (H&E, IHC, and multiplex immunofluorescence), conducts advanced spatial analysis, and delivers actionable insights. These insights empower pathologists and researchers with an AI-powered data-rich action plan, paving the way for more informed decisions in the development of next-generation treatments such as bi-specifics, antibody-drug conjugates (ADCs), and immunotherapy. Nucleai is working with more than 60 percent of the Top 20 biopharma companies in the world, and has an ecosystem of partners across diagnostics, contract research organizations (CROs), and life sciences tools companies.

Nucleai has raised $60.5M in total funding across 4 rounds. The company is currently at the B stage. Key investors include M Ventures, Debiopharm Innovation Fund, Vertex Ventures Israel.

Nucleai was founded in 2017 by Avi Veidman (Co-founder & CEO), Eliron Amir (Co-founder & COO), Lotan Chorev (Co-founder & VP R&D).

Nucleai operates in Health Tech & Life Sciences, Digital Healthcare, Medical Decision Support, with core technologies in Artificial Intelligence, Machine Learning, Computer Vision, Data Storage, Cloud, Platforms & Interfaces, Software. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Healthcare, Providers, Laboratories.

Nucleai is based in Ein Zeitim St 4, Tel Aviv-Yafo, Israel, Center District. The company also has offices abroad.